Biolinerx (BLRX) Posts Q1 Loss of 1c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Aegis Keeps BioLineRx (BLRX) at 'Buy'; Plenty of Catalysts Happening Over Next 12 Months
May 21, 2014 9:26 AM EDTAegis Capital maintained BioLineRx, Ltd. (Nasdaq: BLRX) at Buy with a $7 price target following Q1 results. After markets closed Tuesday, BioLineRx reported Q1 EPS of ($0.01), $0.10 better than the analyst estimate of ($0.11).
Analyst Ram Selvaraju said, The firm ended the quarter with $37.5mm in cash, following a recent financing round that raised $24.1mm in net proceeds from the sale of roughly 9.7mm American... More
